Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Development of a Cabozantinib (Cabometyx) Symptom Management Application for Use in Patients With Renal Cancer

NCT03867045 is registered in ClinicalTrials.gov with Duke University as lead sponsor.

NCT NCT03867045
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03867045 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Development of a Cabozantinib (Cabometyx) Symptom Management Application for Use in Patients With Renal Cancer
Lead sponsor
Duke University
Phase
Not applicable
Overall status
Terminated
Start date
August 21, 2019
Completion date
December 16, 2019
Enrollment
1 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma treated with cabozantinib